FTXH First Trust Nasdaq Pharmaceuticals ETF
Quote as of Oct 09, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 40.45 | Day Range | 40.42 – 41.33 |
| 52-Week Range | 28.77 – 43.52 | Volume | 1.26M |
| Avg Volume | 487.92K | AUM | $1.05B (Oct 10, 2026) |
| Expense Ratio | 0.60% | Yield (TTM) | 0.70% |
| NAV | 40.46 | Premium/Discount | +2.00% indicative |
| Inception | Sep 20, 2016 | Holdings | 50 |
| Issuer | First Trust | Exchange | NASDAQ |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 33738R837 | ISIN | US33738R8372 |
| Management | Not stated in source data | ||
About this ETF
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) operates as an exchange-traded fund. Its primary aim is to mirror the financial performance—both capital appreciation and income generation—of the Nasdaq US Smart Pharmaceuticals Index, prior to any fund-specific fees and expenses. To achieve this, the ETF endeavors to precisely replicate the constituents and their proportionate allocations within that index, striving for a performance correlation of at least 95%.
Description from the fund data provider · profile as of Oct 10, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +1.40% | +7.70% | +21.28% | +25.29% | +41.00% | +17.15% | +9.82% | +7.78% | +7.25% |
| Total return | +1.40% | +7.70% | +21.56% | +25.82% | +42.11% | +18.77% | +11.32% | +9.12% | +8.57% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 09, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.60% | Annual cost of a $10,000 investment | $60.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 10, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 51 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | AbbVie Inc. | ABBV | 7.75% | 301.74K | $83.4M |
| 2 | Eli Lilly and Company | LLY | 7.33% | 66.89K | $78.9M |
| 3 | Pfizer Inc. | PFE | 7.14% | 2.72M | $76.9M |
| 4 | Merck & Co., Inc. | MRK | 7.08% | 523.63K | $76.2M |
| 5 | Johnson & Johnson | JNJ | 7.07% | 291.04K | $76.1M |
| 6 | Viatris Inc. | VTRS | 3.84% | 2.34M | $41.3M |
| 7 | Biogen Inc. | BIIB | 3.75% | 178.57K | $40.3M |
| 8 | Gilead Sciences, Inc. | GILD | 3.71% | 264.36K | $40.0M |
| 9 | Zoetis Inc. | ZTS | 3.49% | 501.76K | $37.5M |
| 10 | Amgen Inc. | AMGN | 3.47% | 89.99K | $37.3M |
| 11 | United Therapeutics Corporation | UTHR | 3.43% | 67.29K | $37.0M |
| 12 | Vertex Pharmaceuticals Incorporated | VRTX | 3.37% | 71.05K | $36.2M |
| 13 | Regeneron Pharmaceuticals, Inc. | REGN | 3.36% | 48.41K | $36.1M |
| 14 | Incyte Corporation | INCY | 3.25% | 310.46K | $35.0M |
| 15 | Bristol-Myers Squibb Company | BMY | 3.18% | 579.05K | $34.2M |
| 16 | Jazz Pharmaceuticals Plc | JAZZ | 2.50% | 122.99K | $26.9M |
| 17 | Exelixis, Inc. | EXEL | 2.40% | 430.94K | $25.8M |
| 18 | Illumina, Inc. | ILMN | 2.31% | 89.35K | $24.9M |
| 19 | Halozyme Therapeutics, Inc. | HALO | 1.59% | 155.32K | $17.2M |
| 20 | Medpace Holdings, Inc. | MEDP | 1.52% | 26.65K | $16.3M |
| 21 | Neurocrine Biosciences, Inc. | NBIX | 1.21% | 91.41K | $13.0M |
| 22 | Alnylam Pharmaceuticals, Inc. | ALNY | 1.20% | 55.41K | $12.9M |
| 23 | Elanco Animal Health Incorporated | ELAN | 1.18% | 554.94K | $12.7M |
| 24 | BioMarin Pharmaceutical Inc. | BMRN | 1.15% | 226.55K | $12.4M |
| 25 | Charles River Laboratories International, Inc. | CRL | 1.05% | 37.43K | $11.3M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.70% | Paid (last 12 months) | $0.2900 |
| Frequency | Quarterly | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Sep 24, 2026 | Last payment | $0.0113 (Sep 30, 2026) |
| Growth 1Y | -37.51% | Growth 3Y / 5Y (ann.) | -11.30% / +4.47% |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Sep 24, 2026 | Sep 24, 2026 | Sep 30, 2026 | $0.0113 |
| Jun 25, 2026 | Jun 25, 2026 | Jun 30, 2026 | $0.0920 |
| Mar 26, 2026 | Mar 26, 2026 | Mar 31, 2026 | $0.0573 |
| Dec 12, 2025 | Dec 12, 2025 | Dec 31, 2025 | $0.1294 |
| Sep 25, 2025 | Sep 25, 2025 | Sep 30, 2025 | $0.1453 |
| Jun 26, 2025 | Jun 26, 2025 | Jun 30, 2025 | $0.0892 |
| Mar 27, 2025 | Mar 27, 2025 | Mar 31, 2025 | $0.0992 |
| Dec 13, 2024 | Dec 13, 2024 | Dec 31, 2024 | $0.1304 |
| Sep 26, 2024 | Sep 26, 2024 | Sep 30, 2024 | $0.1218 |
| Jun 27, 2024 | Jun 27, 2024 | Jun 28, 2024 | $0.1284 |
| Mar 21, 2024 | Mar 22, 2024 | Mar 28, 2024 | $0.0676 |
| Dec 22, 2023 | Dec 26, 2023 | Dec 29, 2023 | $0.1232 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 17.32% / 17.25% | Sharpe 1Y / 3Y | 2.44 / 0.956 |
| Max drawdown 1Y / 3Y | -7.47% / -19.51% | Sortino 1Y | 4.22 |
| Beta vs S&P 500 (3Y) | 0.528 | Correlation vs S&P 500 (1Y) | 0.296 |
| Downside deviation 1Y | 10.04% | Risk-free rate used | 4.05% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 11, 2026. Formulas →
Liquidity
| Volume today | 1.26M | Average volume | 487.92K |
| AUM | $1.05B | Premium/Discount | +2.00% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | -$5.9M | -0.56% | $1.05B → $1.05B |
| 1 Month | -$24.3M | -2.31% | $1.05B → $1.05B |
| 1 Week | -$13.8M | -1.32% | $1.05B → $1.05B |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for FTXH
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.